Current Lab Members

Christopher M. Counter, Ph.D.

Principle Investigator

George Barth Geller Distinguished Professor of Pharmacology & Cancer Biology

Hema Adhikari, Ph.D.

Postdoctoral fellow exploring how oncogenic RAS proteins signal through interrogating their interactomes using proximity-labeling technologies coupled with CRISPR/Cas9 loss-of-function screens.

Özgün Erdoǧan, Ph.D.

Postdoctoral fellow exploring how the relationship between oncoprotein levels and mutation types affect tumor initiation in different tissues using genetically engineered mouse models of human cancers.

 

Seth Zimmerman, Ph.D.

Postdoctoral fellow exploring how phosphatidylinositol metabolism influences tumorigenesis by employing targeted in vivo CRISPR/Cas9 loss-of-function screens. He is also studying how PAX3-FOXO1 promotes the childhood solid cancer  rhabdomyosarcoma by mapping the interactome of this fusion oncoprotein.

Taylor Niehoff

Ph.D. student exploring how the poor expression of oncogenic KRAS imposed by rare codons is overcome by undertaking CRISPR/Cas9 loss-of-function screens for modifiers of rare codon-dependent expression.

Wenceslaus Githiiyi

Technician aiding postdoctoral fellow Dr. Ozgun Erdogan with studies into the relationship between oncoprotein levels and mutation type of RAS genes.